Companies Included: Sanofi S.A., Novo Nordisk
A/S, AstraZeneca Plc., Johnson & Johnson, Merck & Co.
The metabolic disorders drugs market covers medications that are
used in the treatment of metabolic diseases such as diabetes, thyroid, hyperparathyroidism,
hypopituitarism, and hypoadrenalism. Some of the major drugs used in the
treatment of metabolic diseases are Insulin, Methimazole, and Calcimimetics.
The market numbers within this briefing are restricted to pharmaceutical (drug)
treatments and do not cover biologic treatments for these conditions which are
included in a separate briefing.
Order
report at:
The global metabolic disorder drugs
market has been growing in the past years with a CAGR of almost 12%. The year
2017 recorded high growth in this market with a net market value more than 30%
higher than that of 2013, as per TBRC’s in-house consultants.
TBRC’s latest report show the historic
and future trends in the market for each year with sourced reasons to support
the growth claims.
The report also shows the global
metabolic disorder drugs market to grow at a higher CAGR by 2021 as compared to
2017, along with geographies best suited for investments with highest return
rate.
Download
sample report at:
The Food and Drug Administration (FDA)
has approved various enzyme replacement therapies for the treatment of
metabolic disorders. Enzyme replacement therapy is used for treatment of rare
genetic disorders through purified human, animal or recombinant enzymes. In
December 2015, the FDA approved an enzyme replacement therapy Kanuma that can
be used to treat adult and pediatric patients suffering from lysosomal acid
lipase deficiency, a metabolic disorder that causes problems with the breakdown
and use of fats and cholesterol in the body. Similarly, in October 2015, the FDA
had announced the approval of Strensiq, a drug that can be used for the
treatment of perinatal, infantile and juvenile-onset hypophosphatasia, which is
a metabolic disorder affecting multiple body systems. Companies included in the
report are Sanofi S.A., Novo Nordisk A/S, AstraZeneca Plc., Johnson &
Johnson, and Merck & Co.
About
The Business Research Company:
The Business Research Company is a
Business Intelligence Company which excels in company, market and consumer
research. It has offices in the UK, the US and India and a network of trained
researchers in 15 countries globally.
Contact
Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
No comments:
Post a Comment